Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
The "alarming prevalence rate" of diabetes means that "with a slew of effective formulations in the pipeline, competition in the market will be turned up a few notches".
That is the view of researchers at Frost & Sullivan who have issued a new analysis of the European diabetes market. The report notes that the latter earned revenues of $8.60 billion in 2010 and estimates this to reach approximately $13.97 billion in 2017, a compound annual growth rate of 7.2% from 2010-2017.
http://www.pharmatimes.com/Article/...ill_drive_European_diabetes_market_-_F_S.aspx
That is the view of researchers at Frost & Sullivan who have issued a new analysis of the European diabetes market. The report notes that the latter earned revenues of $8.60 billion in 2010 and estimates this to reach approximately $13.97 billion in 2017, a compound annual growth rate of 7.2% from 2010-2017.
http://www.pharmatimes.com/Article/...ill_drive_European_diabetes_market_-_F_S.aspx
